PDCD1 and neoplasm: Overexpression of PD-L1 in tumor cells and tumor-infiltrating lymphocytes, not only correlated with poor disease outcomes in multiple human cancers [4], but also predicted a better response to anti-PD-1/PD-L1 blockade [5].